

To,

Date: 27.01.2022

1. BSE Limited P.J. Towers, Dalal Street, Mumbai-400 001	2. Metropolitan Stock Exchange of India Limited 205(A), 2 nd Floor, Piramal Agastya Corporate Park, Kamani Junction, LBS Road, Kurla (West), Mumbai-400 070
--	--

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 27.01.2022

Ref: Company's letter dated 19.01.2022

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of DrHabeebullah Life Sciences Limited held on Thursday, 27.01.2022 at 3:30 p.m. at the registered office of the Company at 6-3-354/13/B2, Flat. No. B2, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad-500034, Telangana, the following were considered and approved:

1. Unaudited financial results for the quarter ended 31.12.2021. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 31.12.2021. **(Enclosed)**


The meeting concluded at 6:00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,
For Dr Habeebullah Life Sciences Limited


K. Krishnam Raju
Executive Chairman
DIN: 00874650



Encl: as above

Dr Habeebullah Life Sciences Ltd

Regd. Off & Corp Off : 6-3-354/13/B2, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad-500082
.CIN No.: L85110TG1996PLC099198. Email: cs@drhsl.com, info@drhsl.com, pcproductsindia@gmail.com
Contact No.: 9490424639, Website : www.drhsl.com

PART-I							(Rs in Lakhs)
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED 31ST DECEMBER, 2021							
Sr.No	Particulars	Quarter ended			Year to date figures		Previous Year ended 31-03-2021
		3 Months ended 31-12-2021	Corresponding 3 months ended in previous year 31-12-2020	Preceding 3 months ended 30-09-2021	For current period 9 Months ended 31-12-2021	For previous period 9 Months ended 31-12-2020	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
I	Revenue from Operations	-	-	-	-	1.30	1.30
II	Other Income	4.17	3.74	4.06	12.18	10.92	14.77
III	Total Revenue (I+II)	4.17	3.74	4.06	12.18	12.22	16.07
IV	Expenses	-	-	-	-	-	-
	Cost of Material Consumed	-	-	-	-	0.19	0.19
	Employee benefits expense	2.76	7.52	2.76	6.19	32.48	33.17
	Depreciation and Amortisation expense	0.13	0.26	0.13	0.40	0.79	0.96
	Other Expenses	2.95	14.09	3.06	13.56	53.70	58.72
	Total Expenses	5.84	21.87	5.95	20.15	87.16	93.04
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(1.67)	(18.13)	(1.89)	(7.97)	(74.94)	(76.97)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(1.67)	(18.13)	(1.89)	(7.97)	(74.94)	(76.97)
VIII	Tax Expense:	-	-	-	-	-	-
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(1.67)	(18.13)	(1.89)	(7.97)	(74.94)	(76.97)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(1.67)	(18.13)	(1.89)	(7.97)	(74.94)	(76.97)
XIV	Other Comprehensive Income	-	-	-	-	-	-
	A) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax related to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B) (i) Items that will be reclassified to profit or loss	-	-	-	-	1.42	14.08
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(1.67)	(18.13)	(1.89)	(7.97)	(73.52)	(62.89)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)	-	-	-	-	-	-
	1) Basic	(0.01)	(0.12)	(0.01)	(0.05)	(0.50)	(0.42)
	2) Diluted	(0.01)	(0.12)	(0.01)	(0.05)	(0.50)	(0.42)
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)	-	-	-	-	-	-
	1) Basic	-	-	-	-	-	-
	2) Diluted	-	-	-	-	-	-
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)	-	-	-	-	-	-
	1) Basic	(0.01)	(0.12)	(0.01)	(0.05)	(0.50)	(0.42)
	2) Diluted	(0.01)	(0.12)	(0.01)	(0.05)	(0.50)	(0.42)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1480.87	1,480.87	1,480.87	1,480.87	1480.87


Notes:

- The Unaudited financial results for the Quarter III and 9 months period ended 31, December 2021 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on January 27, 2022. The Statutory Auditors have carried out the Limited Review of the Unaudited Standalone Financial Results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015).
- The Unaudited financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (IND AS) 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India ("SEBI") and Regulation 33 of SEBI (LODR) Regulations, 2015 and SEBI Circular dated 05th July, 2016.
- The company has not done any existing business during this third quarter as the company is trying to move into Bio-Pharma segment. The management is seriously working to restart the business in Bio-Pharma with the new business model at the earliest.
- The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- The subsidiary company (Krisani Bio Sciences Private Limited) has made a private placement as of November 12th, 2021, resulting in a decrease in the proportion of overall ownership in the subsidiary business to 32.91%. Krisani Bio Sciences Private Limited is no longer a subsidiary of Dr Habeebullah Life Sciences Ltd as of November 12, 2021, due to a decrease in shareholding.
- The figures of the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.
- The results are also available on the website of the Company www.drhlsl.com

Place : Hyderabad
Date : January 27, 2022

For DR HABEEBULLAH LIFE SCIENCES LIMITED

K. Krishnam Raju
Executive Chairman (DIN 00874650)






A.M. REDDY & D.R. REDDY

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on unaudited Quarterly Financial results of Dr Habeebullah Life Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


To,
The Board of Directors,
Dr Habeebullah Life Sciences Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Dr Habeebullah Life Sciences Limited ("the Company") for the quarter ended December 31, 2021 and year to date results for the period April 01, 2021 to December 31, 2021 ("the Statement ") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we donot express an audit Opinion.



4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A M Reddy & D R Reddy
Chartered Accountants
FRN:0090685



D.Rama Krishna Reddy
Partner
M.No.209211
UDIN: 22209211AAAAAW9263



Place : Hyderabad
Date: 27/01/2022